Here's how 9 Nifty sectoral indices have performed over last decade, see which sector took lead in 2025
Welcome to TrendMap, your guide to the performance of different investment segments. In this edition, we present a 10-year performance tracker of various domestic market sectors. The annual returns are ranked for 9 key NSE sector indices. Real estate and metal sectors shine in the long run, aided by the infrastructure push, boom in commodity prices, and cyclical recoveries.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
a minute ago
- Business Standard
Lemon Tree Hotels rallies 7% on heavy volumes, nears 52-wk high; here's why
Lemon Tree Hotels share price today Shares of Lemon Tree Hotels rallied 7 per cent to ₹155 on the BSE in Monday's intra-day trade amid heavy volumes after the company's subsidiary Fleur Hotels was declared a successful bidder vide Letter of Award in an e-auction conducted by Delhi Development Authority (DDA) with respect to allotment of land at Nehru Place, New Delhi. The stock was trading close to its 52-week high of ₹162.25 touched on January 2, 2025. At 02:37 PM; Lemon Tree Hotels was quoting 5.5 per cent higher at ₹153.20, as compared to 0.97 per cent rise in the BSE Sensex. The average trading volumes at the counter jumped over three-fold. A combined 6.18 million shares representing 0.78 per cent of total equity of the company changed hands on the NSE and BSE. What's driving Lemon Tree Hotels today? On August 14, 2025, Lemon Tree Hotels in an exchange filing announced that its material subsidiary Fleur Hotels Limited has been declared as the successful bidder in e-auction conducted by Delhi Development Authority (DDA) in respect of prime land parcel admeasuring 2.2 acres in the heart of National Capital located at Nehru Place for development and operations of a 5 Star Hotel. It is set to be a 500+ Key hotel and will be in close proximity to Delhi's top tourist spots and is also situated close to the centre of New Delhi city. The hotel is set to be designed on the lines of 'Aurika SkyCity-Mumbai' with elegant rooms, dining and expansive banquet areas. The said Hotel shall be developed as 'Aurika, Nehru Place', which will mark the debut of Lemon Tree Hotels upper upscale brand in the National Capital Region (NCR), the company said. Brokerages view on Lemon Tree Hotels Aurika is a premium brand of Lemon Tree Hotels which commands superior ARR and positions itself in the upper upscale segment and reports highest EBITDA margins in the portfolio, Currently, the company has Aurika SkyCity which is a 650-room hotel located in Mumbai while it has 2 Aurika hotels (Shimla and Shillong) in the pipeline. Shimla is in an advanced stage while Shillong is expected to come up in 2-3 years, ICICI Securities said. With the addition of Aurika, Nehru Place, Lemon Tree Hotel's expansion in the upper upscale segment increases its potential to further expand its revenue and margin profile by improving the premium mix of the portfolio in the long run, the brokerage firm said in a note. According to IDBI Capital, the management anticipates continued growth in demand, driven by the addition of approximately 1,800 planes in India and improving connectivity through Vande Bharat trains, growing airports, and ambitious highway construction. Lemon Tree Hotels aims to complete renovations for the entire portfolio of owned hotels by FY27, with about 65-70 per cent of 4,300 rooms already completed in the last two and a half years. The company is confident of achieving accelerated growth across its entire portfolio, including owned, leased, managed, and franchised properties, the brokerage firm said. It maintains BUY rating on the stock with a revised target price of ₹177, assigning 17x EV/EBITDA to FY27E. About Lemon Tree Hotels Lemon Tree Hotels is one of India's leading hospitality companies, catering to a wide range of customers – from value-conscious travellers to premium business and leisure seekers. With seven distinct brands – Aurika Hotels & Resorts, Lemon Tree Premier, Lemon Tree Hotels, Red Fox, Keys Prima, Keys Select, and Keys Lite – the group offers experiences across upper upscale, upscale, upper midscale, midscale, leisure, wildlife, and spiritual segments.
&w=3840&q=100)
Business Standard
a minute ago
- Business Standard
Marksans Pharma gains 3% on UK MHRA approval for subsidiary; details here
Marksans Pharma share price: Shares of pharmaceutical company Marksans Pharma were trading higher during intra-day deals on Monday, August 18, 2025. The company's share price rose 3.37 per cent to log an intra-day high of ₹184.60 per share on the National Stock Exchange (NSE). The pharmaceutical stock continued to trade higher on the bourses. At last check, Marksans Pharma shares were quoted at ₹183.27 per share, up 2.63 per cent from the previous close of ₹178.58 on the NSE. A combined total of 0.13 million equity shares of Marksans Pharma, estimated to be valued at ₹24.37 crore, exchanged hands on the NSE and BSE today. Why are Marksans Pharma shares ruling higher on the bourses? The upward movement in Marksans Pharma's share price came after the company announced that its wholly owned subsidiary, Relonchem Limited in the UK, had received marketing authorisation for three of its products. "Our wholly owned subsidiary, Relonchem Limited in the UK, has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (UK MHRA) for the following products: Metformin Hydrochloride Relonchem 500 mg Prolonged Release Tablets, Metformin Hydrochloride Relonchem 750 mg Prolonged Release Tablets, and Metformin Hydrochloride Relonchem 1000 mg Prolonged Release Tablets," Marksans Pharma said in a release. About Marksans Pharma Headquartered in Mumbai, Marksans Pharma is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations in global markets. The company's key focus areas lie in both over-the-counter (OTC) and prescription drugs, with wide-ranging applications across therapeutic areas such as pain management, cough and cold, digestive health, cardiovascular (CVS), central nervous system (CNS), oncology, antidiabetics, and antibiotics, among others. Marksans Pharma's manufacturing facilities in India, the USA, and the UK are approved by several leading regulatory agencies, including the USFDA, UK MHRA, and Australian TGA. Its product portfolio spans major therapeutic segments such as CVS, CNS, anti-diabetic, pain management, gastroenterology, and antiallergics. The company markets its products globally. As of August 18, 2025, the pharmaceutical company had a market capitalisation of ₹8,325.07 crore on the NSE. Marksans Pharma share price history Shares of Marksans Pharma have declined nearly 39 per cent year-to-date (YTD). In contrast, the benchmark Nifty50 has advanced nearly 5 per cent during the same period. Marksans Pharma shares hit their 52-week high of ₹358.70 per share on the NSE on August 28, 2024, while the 52-week low of ₹171 was recorded on April 7, 2024.
Mint
a minute ago
- Mint
Gem Aromatics IPO opens on 19 August: GMP, price band, key dates among 10 top things to know
Gem Aromatics IPO opens for subscription tomorrow, 19 August, 2025. Before the issue opens, here are the GMP, price band, key dates, and other top things investors must know before investing. The Gem Aromatics IPO will be up for subscriptions on August 19, 2025, and end on August 21, 2025. The allotment for Gem Aromatics' IPO is planned to be concluded on August 22, 2025. Gem Aromatics' IPO is a book-built issue of ₹ 451.25 crores. The offering consists of a fresh issue of 0.54 crore shares totaling ₹ 175.00 crores and an offer to sell 0.85 crore shares totaling ₹ 276.25 crores. Gem Aromatics' IPO price range, or price band, is set at ₹ 309.00 to ₹ 325.00 per share. The lot size for an application is 46. Considering the lot size and price band, the minimum investment for retail is ₹ 14,214 (46 shares). The lot size investment for small NII is 14 lots (644 shares) worth ₹ 209,300, while for big NII it is 67 lots (3,082 shares) worth ₹ 10,01,650. The Gem Aromatics IPO will list on the BSE and NSE, with an anticipated listing date of August 26, 2025. Gem Aromatics Limited, founded in October 1997, manufactures specialty ingredients such as essential oils, aroma compounds, and value-added derivatives in India with over two decades of experience. The company offers a wide range of products, including Mother Ingredients and Value-Added Derivatives. Motilal Oswal Investment Advisors Ltd. is the book-running lead manager, while Kfin Technologies Ltd. is the issue's registrar. The promoters of Gem Aromatics y are Vipul Parekh, Kaksha Vipul Parekh, Yash Vipul Parekh, and Parekh Family Trust. Gem Aromatics Ltd.'s revenue increased by 11%, and profit after tax (net profit) increased by 7% during the fiscal years ended March 31, 2025, and March 31, 2024. On August 18, Gem Aromatics IPO GMP (Grey Market premium) stood at +31. This means that Gem Aromatics shares are selling in the grey market at an ₹ 31 premium over the issue price of ₹ 325. Investors anticipate Gem Aromatics shares to be listed at a premium of 9.54%, or ₹ 31, above the upper range of the offering price ( ₹ 325). Disclaimer: The views and recommendations made above are those of individual analysts or brokerage companies and not of Mint. We advise investors to check with certified experts before making any investment decisions.
